The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves huntingtin phosphorylation by Akt

被引:404
作者
Humbert, S
Bryson, EA
Cordelières, FP
Connors, NC
Datta, SR
Finkbeiner, S
Greenberg, ME
Saudou, F [1 ]
机构
[1] Ctr Univ Orsay, Inst Curie, CNRS, UMR 146, F-91405 Orsay, France
[2] Childrens Hosp, Div Neurosci, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA
[4] Univ Calif San Francisco, Gladstone Inst Neurol Disorders, San Francisco, CA 94141 USA
关键词
D O I
10.1016/S1534-5807(02)00188-0
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In the search for neuroprotective factors in Huntington's disease, we found that insulin growth factor 1 via activation of the serine/threonine kinase Akt/PKB is able to inhibit neuronal death specifically induced by mutant huntingtin containing an expanded polyglutamine stretch. The IGF-1/Akt pathway has a dual effect on huntingtin-induced toxicity, since activation of this pathway also results in a decrease in the formation of intranuclear inclusions of mutant huntingtin. We demonstrate that huntingtin is a substrate of Akt and that phosphorylation of huntingtin by Akt is crucial to mediate the neuroprotective effects of IGF-1. Finally, we show that Akt is altered in Huntington's disease patients. Taken together, these results support a potential role of the Akt pathway in Huntington's disease.
引用
收藏
页码:831 / 837
页数:7
相关论文
共 34 条
[1]   Molecular basis for the substrate specificity of protein kinase B; Comparison with MAPKAP kinase-1 and p70 S6 kinase [J].
Alessi, DR ;
Caudwell, FB ;
Andjelkovic, M ;
Hemmings, BA ;
Cohen, P .
FEBS LETTERS, 1996, 399 (03) :333-338
[2]   The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease [J].
Alexi, T ;
Hughes, PE ;
van Roon-Mom, WMC ;
Faull, RLM ;
Williams, CE ;
Clark, RG ;
Gluckman, PD .
EXPERIMENTAL NEUROLOGY, 1999, 159 (01) :84-97
[3]   Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease [J].
Andreassen, OA ;
Dedeoglu, A ;
Ferrante, RJ ;
Jenkins, BG ;
Ferrante, KL ;
Thomas, M ;
Friedlich, A ;
Browne, SE ;
Schilling, G ;
Borchelt, DR ;
Hersch, SM ;
Ross, CA ;
Beal, MF .
NEUROBIOLOGY OF DISEASE, 2001, 8 (03) :479-491
[4]   p53 inhibits α6β4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB [J].
Bachelder, RE ;
Ribick, MJ ;
Marchetti, A ;
Falcioni, R ;
Soddu, S ;
Davis, KR ;
Mercurio, AM .
JOURNAL OF CELL BIOLOGY, 1999, 147 (05) :1063-1072
[5]   Replicating Huntington's disease phenotype in experimental animals [J].
Brouillet, E ;
Condé, F ;
Beal, MF ;
Hantraye, P .
PROGRESS IN NEUROBIOLOGY, 1999, 59 (05) :427-468
[6]   Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway [J].
Brunet, A ;
Datta, SR ;
Greenberg, ME .
CURRENT OPINION IN NEUROBIOLOGY, 2001, 11 (03) :297-305
[7]   Transcriptional dysregulation in Huntington's disease [J].
Cha, JHJ .
TRENDS IN NEUROSCIENCES, 2000, 23 (09) :387-392
[8]   Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease [J].
Chen, M ;
Ona, VO ;
Li, MW ;
Ferrante, RJ ;
Fink, KB ;
Zhu, S ;
Bian, J ;
Guo, L ;
Farrell, LA ;
Hersch, SM ;
Hobbs, W ;
Vonsattel, JP ;
Cha, JHJ ;
Friedlander, RM .
NATURE MEDICINE, 2000, 6 (07) :797-+
[9]   Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice [J].
Cummings, CJ ;
Reinstein, E ;
Sun, YL ;
Antalffy, B ;
Jiang, YH ;
Ciechanover, A ;
Orr, HT ;
Beaudet, AL ;
Zoghbi, HY .
NEURON, 1999, 24 (04) :879-892
[10]   Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery [J].
Datta, SR ;
Dudek, H ;
Tao, X ;
Masters, S ;
Fu, HA ;
Gotoh, Y ;
Greenberg, ME .
CELL, 1997, 91 (02) :231-241